Pharvaris N.V.
No SEC Form 4 filings for $PHVS in the last 30 days.
See all $PHVS insider activity →Bank of America upgraded Pharvaris (PHVS) to Buy with a $44 price target, citing strong trial results for its HAE treatment drug, deucrictibant. The stock closed at $31.41 on Oct. 23. BofA sees substantial upside and notes positive feedback from doctors. The FDA decisions in 2027 could impact the stock.
Analysts made several calls on Friday. Roth initiated Natera and Guardant Health with buy ratings, targeting $475 and growth respectively. PhillipCapital upgraded SpaceX to buy with a $250 price target. Seaport reiterated Nvidia as sell due to competitive pressures. Barclays initiated Rush Street Interactive at overweight. Piper Sandler downgraded Deckers to underweight. Jefferies upgraded MSC Industrial to buy. Citizens initiated Microbot Medical at market outperform.
BofA upgraded Pharvaris (PHVS) to Buy with a $44 price target, citing potential in its oral HAE treatment. The stock trades at $30.68, up 10.6% in a week. Positive phase 3 data and strong analyst ratings highlight its prospects, despite risks like market adoption and competition.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning PHVS (Pharvaris N.V.). Coverage has skewed bullish: 4 bullish, 1 neutral, and 0 bearish.
Recent PHVS coverage spans financial news, insider activity and technology.
Positive trial data and analyst upgrade should drive buying interest.
Buy upgrade may lift stock.
Analyst upgrade likely lifts sentiment and supports upside potential.
Positive Phase 3 data reduces clinical risk and sets up a near‑term regulatory filing.
Positive pivotal Phase 3 readout increases probability of NDA/MAA approval for deucrictibant IR and supports risk-on positioning into FDA review.
AlphAI scores every news story that mentions PHVS with an AI model for sentiment and relevance, and aggregates insider trades from Pharvaris N.V.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Bank of America upgraded Pharvaris (PHVS) to Buy with a $44 price target, citing strong trial results for its HAE treatment drug, deucrictibant. The stock closed at $31.41 on Oct. 23. BofA sees substantial upside and notes positive feedback from doctors. The FDA decisions in 2027 could impact the stock.
2 min readAnalysts made several calls on Friday. Roth initiated Natera and Guardant Health with buy ratings, targeting $475 and growth respectively. PhillipCapital upgraded SpaceX to buy with a $250 price target. Seaport reiterated Nvidia as sell due to competitive pressures. Barclays initiated Rush Street Interactive at overweight. Piper Sandler downgraded Deckers to underweight. Jefferies upgraded MSC Industrial to buy. Citizens initiated Microbot Medical at market outperform.
2 min readBofA upgraded Pharvaris (PHVS) to Buy with a $44 price target, citing potential in its oral HAE treatment. The stock trades at $30.68, up 10.6% in a week. Positive phase 3 data and strong analyst ratings highlight its prospects, despite risks like market adoption and competition.
1 min readPharvaris (PHVS) reported that its Phase 3 study of deucrictibant XR for hereditary angioedema (HAE) met all endpoints, reducing attack rates by 83%. The company plans to file for FDA approval in H1 2027. PHVS stock closed at $31.12, up 0.58% in after-hours trading.
3 min readPharvaris (PHVS) announced positive results from the RAPIDe-3 study of deucrictibant IR for treating HAE attacks, published in The Lancet. The treatment showed rapid symptom relief and resolution, with a well-tolerated safety profile. The company's NDA and MAA for deucrictibant IR are under regulatory review, with a PDUFA target date of April 23, 2027.
5 min readH.C. Wainwright reiterated a Buy rating and $60 price target on Pharvaris (PHVS) due to positive Phase 3 data for deucrictibant, showing an 83% reduction in HAE attacks. The firm sees potential in treating acquired angioedema and expects FDA approval by April 2027. PHVS shares are down 19% since September 2026, trading at $30.49 with a $2.14B market cap. Analysts project significant upside, with price targets ranging from $41 to $79.
2 min readPharvaris (PHVS) published a study in Advances in Therapy showing HAE patients prefer oral prophylaxis over injections due to convenience. The analysis, based on data from 1,131 patients, found treatment satisfaction was influenced by portability, administration route, and efficacy. PHVS is developing oral bradykinin B2 receptor antagonists for HAE. The stock closed at $31.19 on October 2, 2026.
2 min readMonges Viviane sold 11,969 shares of Pharvaris N.V. (PHVS) at $33.05 ($0.40M total) on 2026-09-23.
1 min readNassif David W. (CFO / CLO) sold 6,000 shares of Pharvaris N.V. (PHVS) at $36.47 ($0.22M total) on 2026-09-21.
1 min readLu Peng (President) sold 100,000 shares of Pharvaris N.V. (PHVS) at $35.00 ($3.50M total) on 2026-09-17.
1 min read
